Ann: Creso Pharma Anticipates Increasing Q4 2021 Swiss Revenue, page-8

Unfortunately not many people understand that here. Quarter on quarter, they continue to report increased sales, however their increased costs are up much higher. It's a losing business model to date when a Company can't stop the bleeding (most likely intentionally - see below).

However, as previously established it's in EverBlu Capital and Adam Blumenthals best interest to continue with high costs and expenditure, to need to raise capital and get even richer off the fees.

There's a reason why they call it a "conflict of interest" and the ASX should definitely put safe guards in place to protect shareholder interests when this happens - won't happen though.

Here's hoping they can actually report an increase in revenue while decreasing costs.